Cargando…

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

INTRODUCTION: The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doody, Rachelle S, Raman, Rema, Sperling, Reisa A, Seimers, Eric, Sethuraman, Gopalan, Mohs, Richard, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Sun, Xiaoying, Ernstrom, Karin, Thomas, Ronald G, Aisen, Paul S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461930/ https://www.ncbi.nlm.nih.gov/pubmed/26064192 http://dx.doi.org/10.1186/s13195-015-0121-6

Ejemplares similares

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation
por: Hajós, Mihály, et al.
Publicado: (2013)

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
por: Hölttä, Mikko, et al.
Publicado: (2016)

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2015)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
por: Kirn, Dylan R., et al.
Publicado: (2023)

Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site
por: Uemura, Kengo, et al.
Publicado: (2010)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Presenilin/γ-Secretase and Inflammation
por: Saura, Carlos A.
Publicado: (2010)

γ-Secretase in Alzheimer’s disease
por: Hur, Ji-Yeun
Publicado: (2022)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020)

γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing
por: Weber, Tobias A., et al.
Publicado: (2021)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021)

Structure-function relationship of γ-secretase
por: Tomita, Taisuke
Publicado: (2012)

The dynamic conformational landscape of γ-secretase
por: Elad, Nadav, et al.
Publicado: (2015)

Presenilins and γ-Secretase in Membrane Proteostasis
por: Oikawa, Naoto, et al.
Publicado: (2019)

The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition
por: Han, Jianxun, et al.
Publicado: (2009)

Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators
por: Jung, Joo In, et al.
Publicado: (2014)

Development of a High-Throughput Assay for Screening of γ-Secretase Inhibitor with Endogenous Human, Mouse or Drosophila γ-Secretase
por: Wang, Lie-Feng, et al.
Publicado: (2009)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

Biogenesis of γ-secretase early in the secretory pathway
por: Kim, Jinoh, et al.
Publicado: (2007)

Effects of γ-secretase inhibitors in mouse colon
Publicado: (2012)

Mechanism of Intramembrane Cleavage of Alcadeins by γ-Secretase
por: Piao, Yi, et al.
Publicado: (2013)

Structural basis of human γ-secretase assembly
por: Sun, Linfeng, et al.
Publicado: (2015)

γ-Secretase: a multifaceted regulator of angiogenesis
por: Boulton, Michael E, et al.
Publicado: (2008)

The γ-secretase complex: from structure to function
por: Zhang, Xian, et al.
Publicado: (2014)

γ‐Secretase Dependent Nuclear Targeting of Dystroglycan
por: Leocadio, Daniel, et al.
Publicado: (2016)

Mechanisms of γ-Secretase Activation and Substrate Processing
por: Bhattarai, Apurba, et al.
Publicado: (2020)

Defining Mild Stroke: Outcomes Analysis of Treated and Untreated Mild Stroke Patients
por: Spokoyny, Ilana, et al.
Publicado: (2015)

Attitudes about involvement in hypothetical clinical trial protocols in Mexican and Mexican-American at risk for autosomal dominant Alzheimer’s disease
por: Zuno-Reyes, Angélica, et al.
Publicado: (2022)

Enzyme–substrate interface targeting by imidazole‐based γ‐secretase modulators activates γ‐secretase and stabilizes its interaction with APP
por: Petit, Dieter, et al.
Publicado: (2022)

Interplay between α-, β-, and γ-Secretases Determines Biphasic Amyloid-β Protein Level in the Presence of a γ-Secretase Inhibitor
por: Ortega, Fernando, et al.
Publicado: (2013)

γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP)
por: Lessard, Christian B., et al.
Publicado: (2015)

The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
por: Chávez-Gutiérrez, Lucía, et al.
Publicado: (2012)

Presenilin/γ-Secretase Regulates Neurexin Processing at Synapses
por: Saura, Carlos A., et al.
Publicado: (2011)

Presenilins and the γ-secretase: still a complex problem
por: Small, David H, et al.
Publicado: (2010)

The very many faces of presenilins and the γ-secretase complex
por: Smolarkiewicz, Michalina, et al.
Publicado: (2013)

γ-Secretase Components as Predictors of Breast Cancer Outcome
por: Peltonen, Hanna M., et al.
Publicado: (2013)

How γ-secretase hits a moving target
por: Sanders, Charles R
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7j7oa6jrfhkf1nbvmn41903c97